Mantle Cell Lymphoma Treatment Study
Lymphoma is the general name for many related subtypes of cancer that arise from a type of white blood cell called a “lymphocyte.” Lymphoma is divided into two major categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Mantle cell lymphoma (MCL) is one of about 70 different subtypes of NHL and mantle cell results from a malignant transformation of a B lymphocyte in the outer edge of a lymph node follicle (the mantle zone).
The purpose of this phase 1b study is to evaluate the safety and effectiveness, both good and bad of the study drug, ACP-196 (acalabrutinib). ACP-196 is a type of drug that blocks proteins inside cells that help cells live and grow. It is possible that the study drug may kill the cancer cells or stop them from growing.
In this study, subjects with MCL, whose disease has relapsed or failed to respond to anticancer therapy or who have never been treated for their MCL will be assigned to the study drug treatment. ACP-196 will be given twice daily by mouth along with rituximab (given as IV infusion) and bendamustine (given as IV infusion) to see if it will slow or stop a subject’s mantle cell lymphoma from getting worse.
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Have MCL with monoclonal B cells that have a chromosome translocation t(11:14) (q13;q32) and/or overexpress cyclin D1.
- Have MCL requiring treatment and for which no prior therapies have been received.
- Have disease that has relapsed after or has been resistant to 1 or more prior therapies for MCL, and now requires further treatment.
This is a partial list of elgibility requirements.